Table of Content

Table of Contents

1          Executive Summary

2          Introduction

3          Stakeholder and Technology Analysis of Major Pharmaceutical Companies

4          Stakeholder and Technology Analysis of Technology Companies

4.1       Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.2       Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.3       Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.4       Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies

 

5          Pipeline Analysis of T-Cell and NK Cell Engaging Bispecific Antibodies

5.1       Tumor Targeting & Effector Cell Engagement

5.2       Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies

5.3       Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies

5.4       Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies

5.5       Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies

5.6       Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies

5.7       Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies

5.8       Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies

5.9       Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies

 

6          Sources of Financing and Partnering Deals of Technology Companies

 

  1. Company Profiles

7.1.      Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies

7.2       Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.3       Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.4       Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.5       7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies

  • AbbVie
  • Abpro
  • Adimab
  • Affimed Therapeutics
  • Alligator Bioscience
  • Amgen
  • Amphivena Therapeutics
  • Aptevo Therapeutics
  • Arbele
  • Astellas Pharma
  • AstraZeneca
  • BenHealth Biopharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Crescendo Biologics
  • CytomX Therapeutics
  • Dragonfly Theraputics
  • Eli Lilly
  • GEMoaB Monoclonals
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • GT Biopharma
  • Harpoon Therapeutics
  • IGM Biosciences
  • Immatics Biotechnologies
  • Immunocore
  • Innate Pharma
  • Inovio Pharmaceuticals
  • Janssen
  • Lava Therapeutics
  • MacroGenics
  • Maverick Therapeutics
  • Merck & Co.
  • Merus
  • Mogam Institute for Biomedical Research (MIBR)
  • Molecular Partners
  • NJCTTQ
  • Novartis
  • Numab
  • Pfizer
  • Pieris Pharmaceuticals
  • PsiOxus Therapeutics
  • Regeneron Pharmaceuticals
  • Revitope Oncology
  • Roche
  • Sanofi
  • Servier
  • Takeda Pharmaceutical Co.
  • TeneoBio
  • VBL Therapeutics
  • Xencor
  • YZY Biopharma
  • Zymeworks

 

8          Technology Profiles

8.1       Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.2       Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.3       Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie

8.4       Novel „Special“ T-Cell and NK Cell Engaging Bispecific Antibody Technologies

  • ADAPTIR Bispecific, Modular Protein Technology
  • Anticalin Technology
  • ART-Ig Technology
  • Asymmetric head-to-tail 2+1 T-Cell Bispecific (2+1 TCB) IgG antibody platform
  • Azymetric Platform
  • BEAT Technology: Bispecific Engagement by Antibodies based on the T Cell Receptor
  • Biclonics Technology
  • Bispecific IgM Antibodies
  • COBRA Technology
  • CODV-Ig Technology
  • DARPin Multispecifics
  • DNA-Encoded Bi-specific T Cell Engagers (dBiTEs)
  • DuoBody Technolog
  • DVD-Ig Bispecific Antibody Technology
  • GammaDelta T-cell Engager Platform
  • HLE-BiTE Bispecific T Cell Engager Technology
  • Humabody Technology
  • Human Heavy Chain Antibody (UniAb) Platform for Bispecifics
  • ImmunoTherapy Antibody (ITab) technology platform
  • ITE Technology
  • Knobs-into-holes Technology
  • MATCH Technology
  • MultiMab Technology with TetraBi Format
  • NK Cell Engager (NKCE) Technology
  • ROCK Platform: Redirected Optimized Cell Killing
  • RUBY Technology
  • T cell Engaging Antibody Circuits (TEACs)
  • T cell-engaging Bispecific Probody Technology
  • T-Cell Engaging Full Length Bispecific Antibody Platform
  • TCER: Bispecific T-cell Engaging Receptor Molecules
  • TCR-based ImmTAC Technology
  • TriKE and TetraKE Technologies
  • TriNKET Technology
  • TriTAC & ProTriTAC Technologies
  • Tumor-Specific Immuno-Gene Therapy (T-SIGn)
  • Veloci-Bi Technology
  • XmAb Bispecific Fc Technology
  • YBody Bispecific Antibody Technology

 

9          Drug and Drug Candidate Profiles

9.1.1    A-319

9.1.2    A-337

9.1.3    ABBV-428

9.1.4    ABP-100

9.1.5    ABP-110

9.1.6    ABP-150

9.1.7    AFM13

9.1.8    AFM14

9.1.9    AFM26

9.1.10  ALG.APV-527

9.1.11  AMG 160

9.1.12  AMG 212

9.1.13  AMG 330

9.1.14  AMG 420

9.1.15  AMG 424

9.1.16  AMG 427

9.1.17  AMG 562

9.1.18  AMG 596

9.1.19  AMG 673

9.1.20  AMG 701

9.1.21  AMG 757

9.1.22  AMV564

9.1.23  Anti-FLT3

9.1.24  Anti-ROR1

9.1.25  APVO436

9.1.26  ARB-201

9.1.27  Blincyto

9.1.28  BMS-986277

9.1.29  CB307

9.1.30  CC-93269

9.1.31  ERY974

9.1.32  GBR1302

9.1.33  GBR1342

9.1.34  GBR1372

9.1.35  GEM3PSCA

9.1.36  GEM333

9.1.37  GEN3013

9.1.38  HPN217

9.1.39  HPN328

9.1.40  HPN424

9.1.41  HPN536

9.1.42  IGM2323

9.1.43  IMC-C103C

9.1.44  IMC-F106C

9.1.45  IMCgp100

9.1.46  IMCnyeso

9.1.47  IPH61

9.1.48  JNJ-63709178

9.1.49  JNJ-6389808

9.1.50  JNJ-64007957

9.1.51  JNJ-64407564

9.1.52  JNJ-67571244

9.1.53  M701

9.1.54  M802

9.1.55  MCLA-117

9.1.56  MCLA-145

9.1.57  MG1122

9.1.58  MGD006

9.1.59  MGD007

9.1.60  MGD009

9.1.61  MGD014

9.1.62  MO0310

9.1.63  ND021

9.1.64  NG-641

9.1.65  OXS-1615

9.1.66  OXS-3550

9.1.67  OXS-C3550

9.1.68  PF-06671008

9.1.69  PF-06863135

9.1.70  PRS-342

9.1.71  REGN1979

9.1.72  REGN4018

9.1.73  REGN5458

9.1.74  RG6026

9.1.75  RG6160

9.1.76  RG6194

9.1.77  RG7802

9.1.78  RG7827

9.1.79  RG7828

9.1.80  SAR440234

9.1.81  TNB-383B

9.1.82  TNB-486

9.1.83  TNB-585

9.1.84  TSA(1)-CD28 & TSA(2)-CD28

9.1.85  VB-600

9.1.86  XmAb13676

9.1.87  XmAb14045

9.1.88  XmAb18087

9.1.89  XmAb23104

9.1.90  Y111

 

10        References



Tables

Tables in the Text

Table 1           Big Pharma’s In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 2           Big Pharma’s Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 3           Big Pharma’s Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 4           Big Pharma’s Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 5           Economic Terms of Big Pharma’s Collaboration & Licensing Agreements for T-Cell & NK Cell Engaging Bispecific Antibody Technologies

Table 6           Main Characteristics of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 7           Safety and Effector Cell Features of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 8           Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma’s Proprietary T-cell and NK Cell Engaging Bispecific Antibodies

Table 9           Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 10         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 11         Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 12         Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 13         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 14         Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 15         Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 16         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 17         Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 18         Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 19         Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies

Table 20         Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 21         Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 22         Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 23         Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 24         Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies

Table 25         Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 26         Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 27         Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 28         Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 29         Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 30         Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies

Table 31         Amgen’s Bispecific T-Cell Engager Pipeline

Table 32         Celgene’s Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies

Table 33         Janssen’s Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 34         Pfizer’s T-cell Engaging Bispecific Antibody Pipeline

Table 35         Roche’s Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies

Table 36         Sanofi’s Bispecific T-Cell and NK Cell Engager Pipeline

Table 37         Abpro’s Pipeline of T-Cell Engaging TetraBi Antibodies

Table 38         Merus‘ Biclonics Development Pipeline

Table 39         Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline

Table 40         TeneoBio’s Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies

Table 41         YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 42         Partnering Terms for Zymeworks‘ Azymetric Technology

Table 43         Pipeline of ADAPTIR Molecules from Aptevo Therapeutics

Table 44         MacroGenics‘ Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies

Table 45         Xencor’s Bispecific T-Cell Engaging Antibody Pipeline

Table 46         Generon’s Pipeline of Bispecific ITab Antibodies

Table 47         Harpoon Therapeutics‘ TriTAC Pipeline

Table 48         Affimed Therapeutics‘ T-Cell and NK-Cell Engaging Antibody Pipeline

Table 49         GT Biopharma‘ Pipeline of Tri- and Tetra-Specific NK Cell Engagers

Table 50         Goals and Terms of Immunocore’s Industry Partnering Deals for ImmTAC Technology

Table 51         Immuncore’s Wholly Owned and Partnered Development Pipeline of ImmTACs

Table 52         Blincyto Global Sales

Table 53         Clinical Studies with IMCgp100